Immunai
Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.
About
Immunai decodes the human immune system at unprecedented scale and resolution to facilitate the development of next-generation immune-related therapeutics. Their platform supports drug discovery and development by identifying novel targets, evaluating preclinical candidates, and optimizing clinical trials. They partner with biopharmaceutical companies and research institutions to provide actionable recommendations for advancing therapies. Teams look it up for Healthcare, Immunology, Data.
Frequently asked
What does Immunai do?
Immunai is a Healthcare company that offers Software. Teams look it up for Immunology, Data, Analytics. It is based in New York, United States and was founded in 2019. Public records show about 179 people and $295M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Immunai raised?
Immunai has raised a total of $295M in funding. The most recent round on record is Series B.
Where is Immunai headquartered?
Immunai is headquartered in New York, United States.
When was Immunai founded?
Immunai was founded in 2019.
What industry does Immunai operate in?
Immunai operates in Healthcare, Immunology, Data, Analytics, Personalized Treatment.
How many employees does Immunai have?
Immunai has approximately 179 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.